Chronic Condition Management

Monitoring of arterial stiffness could be a potential target for prediction of renal decline in younger type 2 diabetes patients.

Targeting all eligible patients would be cost-effective, but cost might be reduced by focusing on certain patient subgroups.

Early data shows promise in “real-world” effectiveness.

Physicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.

Previous estimates based on cause of death on death certificates underestimated the problem.

A genetic predisposition to having increased abdominal fat increased risk for diabetes and heart disease, according to a new study.

All-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.

Researchers say theirs is first national study with a large population to examine possible link.

New study indicates vulnerable subgroups of diabetes patients did experience adverse outcomes due to change in health insurance coverage.

New definition opens the door to full Medicare coverage for CGMs.

A new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant.

Direct-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author.

The easy-to-administer test was useful in predicting diabetes risk, and prediabetes status in children and adolescents.

Of 155 conditions, personal healthcare spending on diabetes tops list, according to new study.

French study shows that ICU admissions for and mortality from severe COPD exacerbations are increasing despite improved management methods.

In a small single-center study, a breathlessness, cough and sputum score of 5.0 or greater was a good predictor of exacerbation risk.

Direct-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research.

Patients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.

This slide show highlights the top 10 issues we covered this year on managing treatment of patients with HCV infection.

Patients with stable COPD already using supplemental oxygen should discuss continued use with their physician.

The CAPTURE questionnaire along with a peak flow test could assist primary care physicians with severe COPD diagnosis.

A test for hepatitis B virus should be done for patients beginning treatment with direct-acting antiviral therapy for their hepatitis C, experts advise.

A new study shows all-oral direct-actin antiviral agents for hepatitis C can provide both short- and long-term economic value.

Targeting people who inject drugs may be the pathway to eradication of the hepatitis C virus (HCV), according to a recent review.

Insurance arrangements for direct-acting antivirals, where hepatitis C virus patients share the burden of treatment costs, are ineffective says one researcher.

A real-world study confirms the effectiveness and safety of the all-oral combination of sofosbuvir plus ribavirin for treatment of hepatitis C virus GT2 infection.

U.S. study finds those with HCV three times more likely to drink five or more drinks per day every day vs. those without HCV infections.

HCVcAg tests may cost less and improve diagnostic capacity in settings of high hepatitis C virus prevalence, according to new research.

Removing potential barriers to treat hepatitis C virus is yet another key component to patient access, notes lead researcher.

Lead researcher says economic impact of hepatitis C virus will increase unless action is taken now.